Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

about

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q58560605-F8BE87B7-F792-43BB-ABD5-7300855EACEB

P2860

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Item

http://www.wikidata.org/entity/Q46427111

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@en

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@nl

type

Item

label

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@en

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@nl

prefLabel

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@en

Benefit of continuous treatmen ...... in the randomized FIRST trial.

@nl

P1476

Benefit of continuous treatmen ...... in the randomized FIRST trial

@en

P2093

A Corso

http://www.w3.org/2001/XMLSchema#string

A Ervin-Haynes

http://www.w3.org/2001/XMLSchema#string

A-M Stoppa

http://www.w3.org/2001/XMLSchema#string

G Chen

http://www.w3.org/2001/XMLSchema#string

G Marit

http://www.w3.org/2001/XMLSchema#string

H Demuynck

http://www.w3.org/2001/XMLSchema#string

J Marek

http://www.w3.org/2001/XMLSchema#string

L-O Mugge

http://www.w3.org/2001/XMLSchema#string

M Granell

http://www.w3.org/2001/XMLSchema#string

N J Bahlis

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.

International uniform response criteria for multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.

Part II: role of maintenance therapy in transplant-ineligible patients.

Association of response endpoints with survival outcomes in multiple myeloma.

P2888

leu.2017.111

P304

2435-2442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.111

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hareth Nahi

Shang-Yi Huang

P577

2017-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28373701

http://www.w3.org/2001/XMLSchema#string

P932

5668494

http://www.w3.org/2001/XMLSchema#string

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

about

P2860

P2860

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932